Biotechnology - Anti-Arthritics/Rheumatics

Filter

Popular Filters

1 to 25 of 105 results

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

21-08-2014

Surveyed managed care organizations (MCOs) anticipate that their costs of covering biologic treatments…

Anti-Arthritics/RheumaticsBiotechnologyFinancialHealthcareImmunologicals

Daiichi Sankyo initiates testing of etanercept biosimilar in Japan

Daiichi Sankyo initiates testing of etanercept biosimilar in Japan

20-08-2014

Japanese drug major Daiichi Sankyo says it has started the Phase III trial of CHS-0214, an investigational…

Active rheumatoid arthritisAmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyCoherus BioSciencesDaiichi SankyoEnbreletanerceptJapanPharmacologyResearchRheumatoid arthritis

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

09-07-2014

Shares of US biotech firm Celgene fell 3.5% in premarket trade, but were up 1.2% $86.75 by mid-morning…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneOtezlaResearchUSA

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

3SBio licenses pegsiticase to Selecta Biosciences to develop the gout drug candidate

18-06-2014

China-based biotech firm 3SBio has entered into an exclusive license with Selecta Biosciences for pegsiticase…

3SBioAnti-Arthritics/RheumaticsBiotechnologyLicensingpegsiticaseSelecta Biosciences

EULAR: Ph III data demonstrate comparability of Epirus' BOW015 to Remicade for RA

EULAR: Ph III data demonstrate comparability of Epirus' BOW015 to Remicade for RA

12-06-2014

USA-based privately-held Epirus Biopharmaceuticals, focused on the development and commercialization…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyBOW015EPIRUS BiopharmaceuticalsinfliximabRemicadeResearch

EULAR: Positive Ph III sarilumab data in RA from Sanofi and Regeneron

EULAR: Positive Ph III sarilumab data in RA from Sanofi and Regeneron

12-06-2014

French drug major Sanofi and partner US biotech firm Regeneron Pharmaceuticals have presented positive…

Anti-Arthritics/RheumaticsBiotechnologyRegeneronResearchSanofisarilumab

EULAR: Sustained outcomes with UCB’s Cimzia in spondyloarthritis

EULAR: Sustained outcomes with UCB’s Cimzia in spondyloarthritis

12-06-2014

Belgium’s leading drugmaker UCB today presented new long-term data on Cimzia (certolizumab pegol) in…

Anti-Arthritics/RheumaticsBiotechnologyCimziaResearchUCB

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

12-06-2014

US drug major Bristol-Myers Squibb has released new data from a Phase IIIb RA trial showing that the…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbOrenciaResearch

Janssen pulls EU application for IV Simponi

19-05-2014

Janssen Biologics, a European subsidiary of US health care giant Johnson & Johnson, says it has withdrawn…

Anti-Arthritics/RheumaticsBiotechnologyEuropeJanssenJohnson & JohnsonRegulationSimponi Injection

Celgene gains rights to Nogra product in potential $1 billion-plus deal

Celgene gains rights to Nogra product in potential $1 billion-plus deal

24-04-2014

US biotech firm Celgene has entered a global license agreement with privately-held Irish company Nogra…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneGED-0301LicensingNogra Pharma

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

Brazil’s Cristalia gains ANVISA approval for production of biosimilar drugs

24-03-2014

The Brazilian drugmaker Cristalia has just taken another step towards its goal of producing biosimilar…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyBrazilCristaliaEnbrelHerceptinMetabolicsNorditropinOncologyProductionRegulationSouth America

Celgene’s Otezla is first oral therapy OKed by FDA for adults with active psoriatic arthritis

23-03-2014

The US Food and Drug Administration on Friday approved US biotech firm Celgene’s Otezla (apremilast),…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneNorth AmericaOtezlaRegulationUSA

Amgen and UCB’s romosozumab shows significant increase in BMD

Amgen and UCB’s romosozumab shows significant increase in BMD

02-01-2014

US biotech firm Amgen and partner UCB of Belgium have announced positive results from a Phase II trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyForteoFosamaxResearchromosozumabUCB

Biologics reimbursement trends in Argentina, Brazil and Mexico

Biologics reimbursement trends in Argentina, Brazil and Mexico

23-12-2013

Novel biologics must demonstrate improvements in efficacy, safety and cost-benefit compared with currently…

Anti-Arthritics/RheumaticsArgentinaBiotechnologyBrazilMalaysiaMarkets & MarketingOncologyPricingSouth America

Biogen Idec and Samsung Bioepis to market anti-TNF biosimilars in Europe

Biogen Idec and Samsung Bioepis to market anti-TNF biosimilars in Europe

17-12-2013

US biotech major Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF…

Anti-Arthritics/RheumaticsBiogen IdecBiosimilarsBiotechnologyEuropeMarkets & MarketingSamsung Bioepis

Brazil’s MoH partners with Merck Serono to invest $430 million in bio-pharma production

Brazil’s MoH partners with Merck Serono to invest $430 million in bio-pharma production

08-11-2013

The Brazilian Ministry of Health is managing a series of product development partnerships and the selection…

Anti-Arthritics/RheumaticsBionovisBiotechnologyFinancialMerck KGaAMerck SeronoOncologyProductionSouth America

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

28-10-2013

Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

US FDA approved auto-injector Otrexup from Antares Pharma for RA

US FDA approved auto-injector Otrexup from Antares Pharma for RA

15-10-2013

Antares Pharma has announced the approval of Otrexup (methotrexate) injection by the US Food and Drug…

Antares PharmaAnti-Arthritics/RheumaticsBiotechnologyNorth AmericaOtrexupRegulation

Inovio reveals success in DNA plasmid technology

Inovio reveals success in DNA plasmid technology

25-09-2013

US drug developer Inovio Pharmaceuticals has demonstrated the success of its new DNA plasmid technology…

Anti-Arthritics/RheumaticsBiotechnologyCNS DiseasesInovio PharmaceuticalsNorth AmericaOncologyResearch

Johnson & Johnson's Stelara gains FDA approval for psoriatic arthritis

24-09-2013

Janssen Research & Development announced that the US Food and Drug Administration has approved Stelara…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechNorth AmericaRegulationStelara Injection

EGA welcomes first biosimilar MAb approvals in Europe

12-09-2013

Following the European Medicines Agency's CHMP recommendation, the European Commission (EC) has just…

Anti-Arthritics/RheumaticsBiotechnologyGenericsPricingRegulation

First biosimilar monoclonal antibody approved in Europe

10-09-2013

US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

1 to 25 of 105 results

Back to top